Kunmi Majekodunmi, MD
Internal Medicine · Glen Burnie, MDNPI 1497791917
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,075 of the $2,704 with a category attached, or 76.7%. 22 manufacturers reported payments, led by AbbVie at 27.5% of the total. Reporting peaked in 2021 at $730 and has fallen 79.0% since, to $153 in 2025.
Across 120 payments — averaging $22.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$745
- Astellas Pharma US Inc$581
- Novo Nordisk$363
- Sunovion Pharmaceuticals Inc.$238
- Sumitomo Pharma America, Inc.$122
- GSK$100
- plus $555 from 16 others
Across 15 payments — averaging $6161.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endo Pharmaceuticals Inc.$92K
What the payments were for
- Food & beverage$2,07577%
- Education$62923%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 26 | $745 |
| Astellas Pharma US Inc | 8 | $581 |
| Novo Nordisk | 19 | $363 |
| Sunovion Pharmaceuticals Inc. | 26 | $238 |
| Sumitomo Pharma America, Inc. | 9 | $122 |
| GSK | 5 | $100 |
| Sanofi-aventis U.S. LLC | 4 | $67 |
| Otsuka America Pharmaceutical, Inc. | 1 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $52 |
| Xeris Pharmaceuticals, Inc. | 2 | $46 |
| Dexcom, Inc. | 1 | $44 |
| Lilly USA, LLC | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Collegium Pharmaceutical, Inc. | 2 | $38 |
| Ardelyx, Inc. | 2 | $30 |
| Atricure, Inc. | 1 | $26 |
| Amgen | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Pfizer | 1 | $14 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$247
How this compares
$2,704 in reported general payments places this provider in the 85th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 113 | $119,895 |
| EliquisApixaban | 221 | $109,033 |
| OzempicSemaglutide | 76 | $92,948 |
| MounjaroTirzepatide | 54 | $67,235 |
| LinzessLinaclotide | 98 | $64,707 |
| JanuviaSitagliptin Phosphate | 52 | $57,890 |
| MyrbetriqMirabegron | 62 | $47,304 |
| TrulicityDulaglutide | 34 | $41,492 |
| VraylarCariprazine Hcl | 20 | $34,792 |
| XareltoRivaroxaban | 63 | $29,843 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 28 | $25,446 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $25,197 |
| FarxigaDapagliflozin Propanediol | 30 | $23,258 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 26 | $23,046 |
| KerendiaFinerenone | 19 | $18,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $14 | $115,918243 claims |
| AbbVieLinzess, Vraylar, Lumigan, Restasis | $745 | $110,642156 claims |
| Lilly USA, LLCMounjaro, Trulicity | $43 | $108,72788 claims |
| Novo NordiskOzempic | $363 | $92,94876 claims |
| Astellas Pharma US IncMyrbetriq | $581 | $47,30462 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $100 | $44,53572 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $67 | $25,44628 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $238 | $8,12013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Glen Burnie
- Marianne MannHighland$2.1M
- Param DedhiaBaltimore$636K
- Curtis RosebraughAshton$418K
- Mark CorriereColumbia$402K
- Gregory PokrywkaTowson$377K
- Shawn DhillonBaltimore$227K
- Brian HarveyAnnapolis$220K
- Jeremy SugarmanBaltimore$210K
- Florence HounPotomac$161K
- Matthew MintzBethesda$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.